Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabian Acker

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|June 10, 2026
Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysisStephanie Herold, Charlotte Wieber, Fabian Acker, et al.
Annals of Hematology|November 26, 2024
Central nervous system relapse after allogeneic HCT in FLT3-mutated AMLKhouloud Kouidri, Fabian Acker, Rosa Toenges, et al.
Future Oncology (London, England)|November 21, 2025
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancerFriederike C Althoff, Fabian Acker, Sebastian Koschade, et al.
Clinical Lung Cancer|September 9, 2023
Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung CancersGiovanni Visonà, Lisa M Spiller, Sophia Hahn, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
International Journal of Cancer|March 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)Fabian Acker, Katharina Wenger, Martin Reck, et al.
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|June 10, 2026
Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysisStephanie Herold, Charlotte Wieber, Fabian Acker, et al.
Annals of Hematology|November 26, 2024
Central nervous system relapse after allogeneic HCT in FLT3-mutated AMLKhouloud Kouidri, Fabian Acker, Rosa Toenges, et al.
Future Oncology (London, England)|November 21, 2025
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancerFriederike C Althoff, Fabian Acker, Sebastian Koschade, et al.
Clinical Lung Cancer|September 9, 2023
Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung CancersGiovanni Visonà, Lisa M Spiller, Sophia Hahn, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
International Journal of Cancer|March 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)Fabian Acker, Katharina Wenger, Martin Reck, et al.
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Pageof 3